The Oral PCSK9 Inhibitor Market Enters High-Growth Phase Owing to the Approval of Mercks LIPFENDRA and the Emergence of Oral PCSK9 Inhibitor Drugs, Including, AstraZenecas AZD0780, Aqurs AQR-008, and Others | DelveInsight

▤ Summary

DelveInsight highlights strong growth in the PCSK9 inhibitor market, driven by cardiovascular disease prevalence and unmet LDL-C control needs. The article emphasizes Merck’s approval of LIPFENDRA as the first oral PCSK9 inhibitor and notes that this could improve convenience and adherence. It also reviews pipeline candidates from AstraZeneca, Aqur Biosciences, Verve Therapeutics, Hengrui Medicine, and others. The report frames these therapies as part of a larger market expansion through 2036 across major regions including the US, EU4, the UK, and Japan.

▦ Linked Companies